XPhyto Therapeutics Corp.

10:50 AM EST - XPhyto Therapeutics Corp. : Announced an update on its rapid COVID-19 (SARS-COV-2) screening test, near-term milestones and the pathway to commercialization. XPhyto and its exclusive diagnostic partner, 3a-Diagnostics GmbH ("3a"), are developing a rapid, disposable, point-of-care lateral flow screening test to detect COVID-19 viral RNA from patient saliva and nasal and throat swabs. On July 6, 2020, the Company announced successful validation of its working prototype for concurrent and independent detection of both the COVID-19 virus and viruses in the broader coronavirus family. 3a's enhanced RNA probe system has demonstrated a detection limit capable of identifying viral RNA at concentrations found in the saliva of symptomatic, pre-symptomatic, and asymptomatic patients as observed and reported by clinicians and scientists in peer reviewed publications. XPhyto Therapeutics Corp. shares C.XPHY are trading off 10 cents at $3.20.